Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
5.22 HKD | +0.38% | +3.57% | -21.39% |
05-02 | Alphamab Oncology's 2023 Loss Narrows as Revenue Rises | MT |
04-10 | Alphamab Oncology Presents Phase-I Clinical Trial Results at 2024 AACR Annual Meeting | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-21.39% | 628M | |
+29.03% | 49.18B | |
-0.10% | 42.11B | |
+43.45% | 40.37B | |
-5.26% | 28.85B | |
+11.48% | 26.09B | |
-22.74% | 18.71B | |
+9.06% | 13.26B | |
+30.01% | 12.32B | |
-1.51% | 11.99B |
- Stock Market
- Equities
- 9966 Stock
- News Alphamab Oncology
- Alphamab Oncology : Nomura Starts Alphamab Oncology at Buy With HK$17.2 Price Target